EVAX Quote, Financials, Valuation and Earnings

Akari Therapeutics PLC has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of --. Evaxion Biotech AS's return on equity of -- beat Akari Therapeutics PLC's return on equity of --.

Evaxion Biotech AS has a consensus price target of --, signalling upside risk potential of 1158.16%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 8147.42%. Given that Akari Therapeutics PLC has higher upside potential than Evaxion Biotech AS, analysts believe Akari Therapeutics PLC is more attractive than Evaxion Biotech AS.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.791, suggesting its less volatile than the S&P 500 by 20.903%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

Evaxion Biotech AS quarterly revenues are $3M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Evaxion Biotech AS's net income of -$1.9M is higher than Akari Therapeutics PLC's net income of -$2.9M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 1.27x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Ascendis Pharma AS has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of -171.53%. Evaxion Biotech AS's return on equity of -- beat Ascendis Pharma AS's return on equity of --.

Evaxion Biotech AS has a consensus price target of --, signalling upside risk potential of 1158.16%. On the other hand Ascendis Pharma AS has an analysts' consensus of $189.82 which suggests that it could grow by 39.33%. Given that Evaxion Biotech AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Ascendis Pharma AS.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.529%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Ascendis Pharma AS quarterly revenues of $63.6M. Evaxion Biotech AS's net income of -$1.9M is higher than Ascendis Pharma AS's net income of -$109.1M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 1.27x versus 21.92x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of --. Evaxion Biotech AS's return on equity of -- beat DBV Technologies SA's return on equity of --.

Evaxion Biotech AS has a consensus price target of --, signalling upside risk potential of 1158.16%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 590.04%. Given that Evaxion Biotech AS has higher upside potential than DBV Technologies SA, analysts believe Evaxion Biotech AS is more attractive than DBV Technologies SA.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Evaxion Biotech AS quarterly revenues are $3M, which are larger than DBV Technologies SA quarterly revenues of --. Evaxion Biotech AS's net income of -$1.9M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 1.27x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of 38.28%. Evaxion Biotech AS's return on equity of -- beat Novo Nordisk AS's return on equity of 88.95%.

Evaxion Biotech AS has a consensus price target of --, signalling upside risk potential of 1158.16%. On the other hand Novo Nordisk AS has an analysts' consensus of $122.11 which suggests that it could grow by 43.66%. Given that Evaxion Biotech AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion Biotech AS is more attractive than Novo Nordisk AS.

Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.

Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.7% to investors and pays a quarterly dividend of $0.52 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 37.96% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Novo Nordisk AS quarterly revenues of $10.5B. Evaxion Biotech AS's net income of -$1.9M is lower than Novo Nordisk AS's net income of $4B. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 27.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 1.27x versus 9.65x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.